SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Anebulo Pharmaceuticals, Inc. ANEB OTC

Other OTC • Healthcare • Biotechnology • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Analyst Price Target

Anebulo Pharmaceuticals, Inc. (ANEB) is a Biotechnology company in the Healthcare sector, currently trading at $0.50. It has a SharesGrow Score of 48/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is ANEB = $6 (+1100% upside).

Net income is $8M (loss), growing at -15.1%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $0 against $12M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 53.36 (strong liquidity). Debt-to-assets is 0%. Total assets: $12M.

Analyst outlook: 3 / 4 analysts rate ANEB as buy (75%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 28/100 (Fail), Future 85/100 (Pass), Income ?/100 (Fail).

$6.00

▲ 1100% Upside

Average Price Target

The 12-month price target for Anebulo Pharmaceuticals, Inc. is $6.00.

ANEB SharesGrow Score Overview

59/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 15/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 67/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 28/100

Gross margin is + market cap

FUTURE 85/100

Analyst outlook — as buy

INCOME 0/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ANEB

ANEB trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $6, implying +1100% from the current price $1. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

ANEB: +0%/yr revenue is, -15.1%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet ANEB: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 53.36 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

ANEB: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.

View details →

Analyst outlook: 3 / 4 analysts rate ANEB as buy (75%). Analyst consensus target is $6 (+1100% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

No analyst coverage available for this stock.

Stock Chart & Stats

Market Data

52-Week Range0.3-3.42

Volume273

Avg Volume (30D)74.54K

Market Cap$20.39M

Beta (1Y)-1.62

Share Statistics

EPS (TTM)-0.25

Shares Outstanding$33.82M

IPO Date2021-05-07

Employees2

CEORichard Anthony Cunningham

Financial Highlights & Ratios

EBITDA$-8.1M

Net Income$-8.48M

Operating Income$-9.22M

Total Cash$11.63M

Net Debt$-11.63M

Total Assets$12.15M

Price / Earnings (P/E)-2

Analyst Forecast

1Y Price Target$6.00

Target High$6.00

Target Low$6.00

Upside+1,100.0%

Rating ConsensusBuy

Analysts Covering4

Buy 75% Hold 25% Sell 0%

Price Target Summary

Company Info

CountryUS

ExchangeOther OTC

CurrencyUSD

ISINUS0345691036

Price Chart

ANEB

Anebulo Pharmaceuticals, Inc. ↗ · Other OTC

Healthcare • Biotechnology

0.30 52WK RANGE 3.42

People Also View

AnaptysBio, Inc.

Mineralys Therapeutics, Inc.

Molecular Partners AG

AN2 Therapeutics, Inc.

PMV Pharmaceuticals, Inc.

Aerovate Therapeutics, Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message